TRT in treatment for hypogonadism and prostate cancer risk

Discussions about the pros and cons of testosterone replacement therapy (TRT) in relation to (a) stimulating risk for prostate cancer in men who have not been diagnosed and (b) recurrence of prostate cancer among men who have been diagnosed and treated often aren’t entirely clear about a very key factor. … READ MORE …

Where the cancer is in your prostate may really matter (sometimes)

A new article in the upcoming December issue of the Journal of Urology has shown that, for men with higher risk prostate cancers, tumors found in the transition zone of the prostate are less “risky” than the same types of cancer when they occur in the peripheral and central zones. … READ MORE …

Anticoagulation therapy and prostate cancer prevention

Today’s “hot news story” in the cancer world is that a very widely used drug called warfarin (often still known as Coumadin) may be able to protect people from  the risks of getting diagnosed with at least some cancers. But … READ MORE …

Risk, genomic risk, and prognosis of risk for prostate cancer metastasis and death

A recently published study in European Urology has again (partially) validated the utility of a specific type of genomic testing as a way to project risk for progressive disease in men initially diagnosed with localized prostate cancer. … READ MORE …

Recovery of normal serum T levels after short-term ADT and radiation therapy

Two matters of concern to many prostate cancer patients who are considering radiation therapy as a treatment for their prostate cancer are : (a) Should I be having a short course of androgen deprivation therapy (ADT) along with the radiation therapy? (b) How well will I recover normal serum testosterone levels after such short-term treatment? … READ MORE …

Why did biochemical control not translate into a survival increase after brachy boost therapy?

The first randomized clinical trial to prove that brachy boost radiotherapy had better oncological outcomes among high-risk patients was the one published by Sathya et al. in 2005. … READ MORE …

MRI data and genomic data are telling us different things about prostate cancer risk

A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)”. … READ MORE …